373 related articles for article (PubMed ID: 9348195)
1. Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant.
Narvaez CJ; Welsh J
Endocrinology; 1997 Nov; 138(11):4690-8. PubMed ID: 9348195
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a vitamin D3-resistant MCF-7 cell line.
Narvaez CJ; Vanweelden K; Byrne I; Welsh J
Endocrinology; 1996 Feb; 137(2):400-9. PubMed ID: 8593782
[TBL] [Abstract][Full Text] [Related]
3. Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells.
Nolan E; Donepudi M; VanWeelden K; Flanagan L; Welsh J
Mol Cell Biochem; 1998 Nov; 188(1-2):13-20. PubMed ID: 9823006
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells.
Simboli-Campbell M; Narvaez CJ; van Weelden K; Tenniswood M; Welsh J
Breast Cancer Res Treat; 1997 Jan; 42(1):31-41. PubMed ID: 9116316
[TBL] [Abstract][Full Text] [Related]
5. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
6. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines.
Elstner E; Linker-Israeli M; Said J; Umiel T; de Vos S; Shintaku IP; Heber D; Binderup L; Uskokovic M; Koeffler HP
Cancer Res; 1995 Jul; 55(13):2822-30. PubMed ID: 7796409
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
Campbell MJ; Reddy GS; Koeffler HP
J Cell Biochem; 1997 Sep; 66(3):413-25. PubMed ID: 9257197
[TBL] [Abstract][Full Text] [Related]
8. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray.
Swami S; Raghavachari N; Muller UR; Bao YP; Feldman D
Breast Cancer Res Treat; 2003 Jul; 80(1):49-62. PubMed ID: 12889598
[TBL] [Abstract][Full Text] [Related]
10. Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo.
Verlinden L; Verstuyf A; Van Camp M; Marcelis S; Sabbe K; Zhao XY; De Clercq P; Vandewalle M; Bouillon R
Cancer Res; 2000 May; 60(10):2673-9. PubMed ID: 10825140
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.
Welsh J
Biochem Cell Biol; 1994; 72(11-12):537-45. PubMed ID: 7654327
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis by 1,25-dihydroxyvitamin D3 in MCF-7 Vitamin D3-resistant variant can be sensitized by TPA.
Narvaez CJ; Byrne BM; Romu S; Valrance M; Welsh J
J Steroid Biochem Mol Biol; 2003 Feb; 84(2-3):199-209. PubMed ID: 12711004
[TBL] [Abstract][Full Text] [Related]
13. The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells.
Myrthue A; Rademacher BL; Pittsenbarger J; Kutyba-Brooks B; Gantner M; Qian DZ; Beer TM
Clin Cancer Res; 2008 Jun; 14(11):3562-70. PubMed ID: 18519790
[TBL] [Abstract][Full Text] [Related]
14. Induction of anchorage-independent growth of JB6 mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3.
Hosoi J; Abe E; Suda T; Colburn NH; Kuroki T
Cancer Res; 1986 Nov; 46(11):5582-6. PubMed ID: 3019530
[TBL] [Abstract][Full Text] [Related]
15. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
Akutsu N; Lin R; Bastien Y; Bestawros A; Enepekides DJ; Black MJ; White JH
Mol Endocrinol; 2001 Jul; 15(7):1127-39. PubMed ID: 11435613
[TBL] [Abstract][Full Text] [Related]
16. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle arrest and apoptosis induced by 1α,25(OH)2D3 and TX 527 in Kaposi sarcoma is VDR dependent.
González-Pardo V; Suares A; Verstuyf A; De Clercq P; Boland R; de Boland AR
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():197-200. PubMed ID: 24316429
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089.
VanWeelden K; Flanagan L; Binderup L; Tenniswood M; Welsh J
Endocrinology; 1998 Apr; 139(4):2102-10. PubMed ID: 9528999
[TBL] [Abstract][Full Text] [Related]
19. Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.
Verlinden L; Verstuyf A; Quack M; Van Camp M; Van Etten E; De Clercq P; Vandewalle M; Carlberg C; Bouillon R
J Bone Miner Res; 2001 Apr; 16(4):625-38. PubMed ID: 11315990
[TBL] [Abstract][Full Text] [Related]
20. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
